Skip to main content

Table 1 Clinical and laboratory variables in Swedish subjects with normal glucose tolerance and in the patients with type 2 diabetes

From: Evaluation of IGFBP-7 DNA methylation changes and serum protein variation in Swedish subjects with and without type 2 diabetes

  

Stockholm Diabetes Prevention Program

Kronan

  

Normal glucose tolerance

Newly diagnosed type 2 diabetes

Type 2 diabetes

N = All (women/men)

 

100 (50/50)

100 (50/50)

140 (54/86)

Age (years)

All

58 (57 to 58)

58 (57 to 58)

61 (60 to 63)†††§§§

Women

57 (55 to 58)

57 (55 to 58)

62 (60 to 64)†††§§§

Men

58 (57 to 59)

58 (57 to 59)

62 (60 to 63)††§§

Body mass index (kg/m2)

All

24.4 (23.8 to 25.1)

30.7 (29.4 to 31.9)†††

29.3 (28.6 to 30.1)†††

Women

23.4 (22.7 to 24.1)

32.2 (30.2 to 34.3)†††

29.7 (28.4 to 30.9)†††§

Men

25.4 (24.4 to 26.4)***

29.1 (27.8 to 30.4)†††*

29.1 (28.1 to 30.2)†††

Waist and hip ratio

All

0.86 (0.84 to 0.87)

0.93 (0.92 to 0.94)†††

0.95 (0.94 to 0.96)†††§

Women

0.82 (0.80 to 0.83)

0.90 (0.88 to 0.91)†††

0.90 (0.89 to 0.92)†††

Men

0.90 (0.88 to 0.91)***

0.96 (0.95 to 0.98)†††***

0.98 (0.97 to 0.99)†††***

Systolic blood pressure (mm Hg)

All

130 (127 to 134)

146 (143 to 150)†††

147 (144 to 150)†††

Women

129 (124 to 133)

147 (141 to 152)†††

149 (145 to 154)†††

Men

132 (126 to 137)

146 (141 to 150)†††

146 (142 to 150)†††

Diastolic blood pressure (mm Hg)

All

80 (78 to 82)

87 (85 to 90)†††

83 (81 to 84)§§§

Women

79 (77 to 82)

86 (83 to 89)††

81 (78 to 83)§

Men

82 (79 to 84)

89 (86 to 92)†††

84 (82 to 86)§

Fasting glucose (mmol/l)

All

4.8 (4.7 to 4.9)

6.8 (6.4 to 7.1)†††

9.0 (8.5 to 9.5)†††§§§

Women

4.6 (4.4 to 4.7)

6.6 (6.2 to 6.9)†††

9.2 (8.4 to 9.9)†††§§§

Men

5.0 (4.9 to 5.1)***

6.9 (6.4 to 7.5)†††

8.9 (8.2 to 9.5)†††§§§

Fasting insulin (pmol/l)a

All

73 (68 to 78)

140 (126 to 156)†††

135 (124 to 147)†††

Women

70 (64 to 76)

150 (130 to 173)†††

138 (123 to 154)†††

Men

77 (69 to 85)

131 (112 to 154)†††

133 (118 to 150)†††

Homeostasis model of assessment: insulin resistancea

All

2.56 (2.37 to 2.78)

6.86 (6.03 to 7.79)

8.53 (7.66 to 9.50)†††§

Women

2.33 (2.11 to 2.59)

7.20 (6.09 to 8.52)

9.00 (7.78 to 10.41)†††

Men

2.82 (2.49 to 3.18)*

6.52 (5.35 to 7.96)

8.25 (7.09 to 9.60)†††

IGF-I (μg/l)a

All

156 (147 to 167)

154 (144 to 165)

117 (107 to 128)†††§§§

Women

154 (141 to 167)

157 (143 to 172)

122 (106 to 141)†§§

Men

159 (145 to 175)

152 (138 to 167)

114 (102 to 128)†††§§§

IGFBP-1 (μg/l)a

All

42 (38 to 47)

23 (20 to 26)†††

17 (14 to 20)†††§§

Women

57 (50 to 65)

28 (24 to 33)†††

18 (14 to 22)†††§§

Men

31 (27 to 37)***

19 (16 to 23)††**

16 (13 to 20)†††

IGFBP-7 (μg/l)a

All

20.5 (18.7 to 22.3)

19.6 (17.8 to 21.5)

19.2 (17.9 to 20.6)

Women

19.0 (16.8 to 21.4)

20.0 (17.0 to 23.5)

18.8 (16.7 to 21.7)

Men

22.1 (19.4 to 25.1)

19.2 (17.3 to 21.3)

19.5 (17.8 to 21.3)

  1. Data were expressed as means (95% confidence interval (CI)) for normally distributed variables and as geometric means (95% CI) for anon-normally distributed variables; Comparison between the three groups was performed by one-way analysis of variance (ANOVA), and if significant followed by Tukey’s post-hoc test; P < 0.05, ††P < 0.01, †††P < 0.001 vs. Stockholm Diabetes Prevention Program NGT and §P < 0.05, §§P < 0.01, §§§P < 0.001 vs. Stockholm Diabetes Prevention Program type 2 diabetes; Comparison of men and women within groups was performed by unpaired t test; *P < 0.05, **P < 0.01, ***P < 0.001.